首页> 外文期刊>Journal of pain and symptom management. >Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.
【24h】

Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.

机译:病人监护仪(2.0版)的验证:针对癌症患者的系统评估工具的综述。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

CONTEXT: The Patient Care Monitor (PCM) is a review of systems survey delivered by means of an electronic patient-reported outcomes (ePRO) data capture system that uses wireless tablet computers. Although the PCM 1.0 is validated, the updated PCM 2.0 has not been validated nor tested in the academic setting. OBJECTIVES: To validate and test the PCM 2.0 in three cancer populations. METHODS: Two hundred seventy-five individuals participated in three clinical trials enrolling breast (n=65), gastrointestinal (n=113), and lung (n=97) cancer patients. Internal consistency was evaluated using Cronbach's alpha coefficients calculated for six PCM subscales (general physical symptoms, treatment side effects, distress, despair, impaired performance, and impaired ambulation) and a Quality-of-Life Index. Construct validity was evaluated through Pearson's correlation between PCM subscales and subscales of the Functional Assessment of Cancer Therapy--General (FACT-G), the M.D. Anderson Symptom Inventory (MDASI), and the Functional Assessment of Chronic Illness Therapy--Fatigue (FACIT-F). The participants had the following characteristics: mean age was 58 years (standard deviation: 11), 52% were females, 79% were whites, 17% were blacks, 62% had no college degree, and 78% had metastatic or recurrent disease. RESULTS: Raw and normalized scores for PCM 2.0 subscales were internally consistent across study cohorts. PCM 2.0 subscales correlated significantly (P<0.05) with the corresponding subscales on FACT-G, MDASI, and FACIT-F, with the exception of FACT-G social well-being, particularly for the lung cancer population. These correlations demonstrated construct validity. PCM 2.0 results followed expected patterns by cancer etiology. Prior reports demonstrate patient satisfaction with PCM 2.0. CONCLUSION: Within three unique academic oncology populations, PCM 2.0 is a valid ePRO instrument for assessing symptoms with seven patient-centered subscale or index domains.
机译:背景:患者护理监护仪(PCM)是对系统调查的回顾,该系统调查是通过使用无线平板电脑的电子患者报告结果(ePRO)数据捕获系统完成的。尽管PCM 1.0已经过验证,但是更新的PCM 2.0尚未在学术环境中得到验证或测试。目的:在三个癌症人群中验证和测试PCM 2.0。方法:275名患者参加了3项临床试验,纳入了乳腺癌(n = 65),胃肠道(n = 113)和肺癌(n = 97)的患者。使用针对六个PCM分量表(一般的身体症状,治疗副作用,困扰,绝望,性能下降和移动障碍)计算的Cronbach'sα系数和生活质量指数评估内部一致性。通过PCM子量表与癌症治疗功能评估-一般(FACT-G),MD安德森症状量表(MDASI)和慢性病治疗-疲劳功能评估(FACIT)的子量表之间的皮尔森相关性评估构建体有效性-F)。参与者具有以下特征:平均年龄为58岁(标准差:11),女性为52%,白人为79%,黑人为17%,没有大专以上学历的人为62%,患有转移性或复发性疾病的人为78%。结果:在整个研究队列中,PCM 2.0分量表的原始分数和标准化分数在内部是一致的。 PCM 2.0分量表与FACT-G,MDASI和FACIT-F的相应分量表显着相关(P <0.05),但FACT-G的社会福祉除外,特别是对于肺癌人群。这些相关性证明构建体的有效性。 PCM 2.0结果遵循癌症病因学的预期模式。先前的报告表明患者对PCM 2.0感到满意。结论:在三个独特的学术肿瘤学人群中,PCM 2.0是一种有效的ePRO仪器,用于评估以患者为中心的七个量表或索引域的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号